TNXP
Tonix Pharmaceuticals Holding Corp.
$17.07
+$0.07(+0.41%)
50
Overall
80
Value
36
Tech
36
Quality
Market Cap
$149.55M
Volume
391.53K
52W Range
$6.76 - $130.00
Target Price
$69.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $53.0K | -- | -- | -- | -- | -- | -- | -- | $7.8M | $10.1M | ||
| Total Revenue | $53.0K | -- | -- | -- | -- | -- | -- | -- | $7.8M | $10.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $4.7M | $7.8M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $53.0K | -- | -- | -- | -- | -- | -- | -- | $3.0M | $2.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $48.2M | $39.0M | $21.3M | $26.3M | $28.8M | $50.5M | $92.3M | $112.1M | $121.4M | $80.1M | ||
| Research & Development | $35.5M | $28.5M | $13.3M | $17.6M | $18.2M | $36.2M | $68.8M | $81.9M | $86.7M | $40.0M | ||
| Research Expense | $35.5M | $28.5M | $13.3M | $17.6M | $18.2M | $36.2M | $68.8M | $81.9M | $86.7M | $40.0M | ||
| Selling, General & Administrative | $12.7M | $10.4M | $7.9M | $8.8M | $10.6M | $14.4M | $23.5M | $30.2M | $34.8M | $40.1M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $30.2M | $34.8M | $40.1M | ||
| General & Administrative Expenses | $12.7M | $10.4M | $7.9M | $8.8M | $10.6M | $14.4M | $23.5M | $30.2M | -- | -- | ||
| Salaries & Wages | $-4.4M | $-3.3M | $-1.8M | $-1.6M | $-1.5M | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-161.0K | $-206.0K | $-64.0K | $-54.0K | $-26.0K | $27.0K | $50.0K | $1.3M | $4.3M | $3.4M | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | -- | $477.0K | $476.0K | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | $500.0K | $600.0K | $600.0K | $600.0K | $300.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-48.2M | $-39.0M | $-21.3M | $-26.3M | $-28.8M | $-50.5M | $-92.3M | $-112.1M | $-118.4M | $-136.7M | ||
| EBITDA | $-47.9M | $-38.6M | $-21.1M | $-26.0M | $-28.6M | $-50.5M | $-92.3M | $-110.8M | $-112.4M | $-125.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $108.0K | $127.0K | $168.0K | $233.0K | $210.0K | $48.0K | $25.0K | $1.9M | $1.7M | -- | ||
| Net Non-Operating Interest Income/Expense | $108.0K | $127.0K | $168.0K | $233.0K | $210.0K | $48.0K | $25.0K | $1.9M | $1.7M | -- | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | -- | -- | $6.2M | ||
| Other Income/Expense | -- | $61.0K | -- | -- | -- | -- | -- | $1.9M | $-1.7M | $-4.1M | ||
| Other Special Charges | -- | $72.0K | -- | -- | -- | -- | -- | -- | $1.7M | $-2.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | $59.0M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $59.0M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-48.1M | $-38.8M | $-21.1M | $-26.1M | $-28.6M | $-50.5M | $-92.3M | $-112.1M | $-116.7M | $-130.0M | ||
| Pre-Tax Income | $-48.1M | $-38.8M | $-21.1M | $-26.1M | $-28.6M | $-50.5M | $-92.3M | $-110.2M | $-116.7M | $-130.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-48.1M | $-38.8M | $-21.1M | $-26.1M | $-28.6M | $-50.5M | $-92.3M | $-110.2M | $-116.7M | $-130.0M | ||
| Net Income (Continuing Operations) | $-48.1M | $-38.8M | $-21.1M | $-26.1M | $-28.6M | $-50.5M | $-92.3M | $-110.2M | $-116.7M | $-130.0M | ||
| Net Income (Discontinued Operations) | $-48.1M | $-38.8M | $-21.1M | $-26.1M | $-28.6M | $-50.5M | $-92.3M | $-110.2M | $-116.7M | $-130.0M | ||
| Net Income (Common Stockholders) | $-48.1M | $-38.8M | $-21.1M | $-29.4M | $-31.1M | $-52.2M | $-92.3M | $-116.9M | $-116.7M | $-130.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-23.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $48.2M | $39.0M | $21.3M | $26.3M | $28.8M | $50.5M | $92.3M | $112.1M | $126.1M | $87.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | -- | -- | -- | -- | $2 | $147 | $562 | $1.8K | $5.3K | $736.3K | ||
| Average Shares Outstanding (Diluted) | -- | -- | -- | -- | $2 | $147 | $562 | $1.8K | $5.3K | $736.3K | ||
| Shares Outstanding | -- | -- | -- | -- | $77 | $506 | $834 | $3.1K | $26.4K | $6.4M | ||
| Basic EPS | -- | -- | $-202.9M | $-171.6M | $-12.4M | $-352.0K | $-166.4K | $-65.4K | $-21.9K | $-176.6 | ||
| Basic EPS (Continuing Operations) | $-1.8B | $-986.2M | $-202.9M | $-171.6M | $-12.4M | $-352.0K | $-166.4K | $-65.4K | $-21.9K | $-176.6 | ||
| Diluted EPS | -- | -- | $-202.9M | $-171.6M | $-12.4M | $-352.0K | $-166.4K | $-65.4K | $-21.9K | $-176.6 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-65.4K | $-21.9K | $-176.6 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | $3.3M | $2.5M | $1.3M | -- | $6.7M | -- | -- | ||
| Gain On Sale Of P P E | -- | $-133.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $12.7M | $10.4M | $7.9M | $8.8M | $10.6M | $14.4M | $23.5M | $30.2M | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $48.8M | ||
| Other Taxes | -- | -- | -- | -- | -- | $-2.2M | $-15.3M | $-9.5M | $-14.5M | $-17.4M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | $3.3M | $2.5M | $1.3M | -- | $6.7M | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | $3.3M | $2.5M | $1.3M | -- | $6.7M | -- | -- | ||
| Rent And Landing Fees | $-6.0M | $-700.0K | $-600.0K | $-500.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNXP | $17.07 | +0.4% | 391.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tonix Pharmaceuticals Holding Corp. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW